Media Search:



Waiting for the Penicillin Moment: my new feature on antiviral drugs for Wired | The Loom

On my way to give a keynote talk at a genome meeting in California, I noticed in the Hartford airport that the April issue of Wired is on the newsstand. And in that issue is a feature I wrote about fighting viruses, based on visits and interviews with scientists exploring new ways of doing battle with these invisible foes. Its not yet on Wireds web site yet (Ill post a link when it goes online), but heres the introduction for a taste:

Theres a moment in the history of medicine thats so cinematic its a wonder no one has put it in a movie. The scene is a London laboratory. The year is 1928. Alexander Fleming, a British microbiologist, is back from a vacation and is cleaning up his workspace. He notices that a speck of mold has invaded one of his cultures of Staphylococcus bacteria. It isnt just spreading through the culture, though. It is killing the bacteria surrounding it.

Fleming rescued the culture and carefully isolated the mold. He ran a series of experiments that confirmed it made a Staphylococcus-killing molecule. And Fleming then discovered it could kill many other species of infectious bacteria as well. I had a clue that here was something good, but I could not possibly know how good it was, he later said.

No one at the time could have known how good it was. In 1928, something as minor as a scraped knee could be a death sentence, because doctors were mostly helpless to stop bacteria infections. Fleming was the first scientist to recognize an antibiotica discovery for which hed later win the Nobel Prize. Penicillin saved countless lives, killing off a wide range of pathogens while causing few side effects. Flemings work also led other scientists to discover more antibiotics, which collectively changed the rules of medicine. Now doctors could prescribe drugs that effectively wiped out most bacteria, without even knowing what kind of bacteria was making their patients sick.

Of course, even if all the bacteria in the world were eradicated, we would still get sick. Viruseswhich cause their own panoply of diseases from colds and the flu to AIDS and Ebolaare profoundly different from bacteria, and so they dont present the same targets for a drug to hit. Penicillin interferes with the growth of bacteria cell walls, for example, but viruses dont have cell walls, because they arent even cells; theyre just genes packed into protein shells. Other antibiotics, such as streptomycin, attack the factories inside bacteria that make new proteins, known as ribosomes. A virus doesnt have ribosomes, but instead uses the ribosome inside its host cell to make new copies of itself.

We do currently have antiviral drugs, but theyre a pale shadow of their counterparts that fight bacteria. Typically, antivirals will drive down the number of virus particles in the body, but they cant wipe the virus out completely. People infected with HIV (for example) can avoid developing AIDS by taking a cocktail of antiviral drugs. But if they stop taking antivirals, the virus will rebound to its former levels in a matter of weeks. They have to keep taking the drugs for the rest of their lives to prevent the viruses from wiping out their immune system.

And antivirals have a limited scope of attack. You can treat your flu with Tamiflu, but it wont cure you of dengue fever or Japanese encephalitis. Scientists have to develop antivirals one disease at a timea labor that can take many years. As a result, we still have no antivirals for many of the worlds nastiest viruses, like Lassa fever and Ebola. We can expect new viruses to leap from animals to our own species in the future, and when those new viruses begin to spread, theres a good chance we wont have any antivirals to help stop them.

Virologists, in other words, are still waiting for their Penicillin Moment. But they might not have to wait forever. Buoyed by advances in molecular biology, a handful of researchers in labs around the US and Canada are trying to engineer a new and unprecedented type of antiviral: a broad-spectrum virus-killer, one that could wipe out viral infections with the same ruthless efficiency that penicillin and Cipro bring to the fight against bacteria. If they succeed, future generations may struggle to imagine a time when we were at the mercy of viruses, just as we struggle to imagine life before Flemings moldy dish.

Excerpt from:
Waiting for the Penicillin Moment: my new feature on antiviral drugs for Wired | The Loom

Joomla jumps to the enterprise

Today, Joomla the name is a phonetic spelling for the Swahili word "Jumla," which means "as a whole"is one of the most popular open source content management systems (CMS), claiming that 2.7 percent of the Web is Joomla-based sites.

If you were to drop Joomla on a straight line with other popular open source CMS projects, it would fall somewhere between WordPress and Drupal. Joomla, which is offered under the General Public License (GPL) version 2.0, is more robust than WordPress, while Drupal is usually favored by those with a developer background.

"Joomla really fits nicely between WordPress and Drupal," says Ryan Ozimek, president of Open Source Matters, a nonprofit organization that provides organization, legal and financial support to the Joomla project.

"We've built a community and have a focus on reaching out to the average user and administrators of a website, but we also give under-the-hood tools to the developers and engineers trying to do something more complex," he adds.

Joomla powers the Children's Hospital Boston social intranet, providing a "Facebook-like" social environment and handling more than 2,500 concurrent users.

Joomla Jibes With Small to Mid-Sized Businesses

With such a large community and abundance of products and services, the small and medium-sized business (SMB) market is where this open source CMS is a strong contender. Small businesses like having access to thousands of add-ons that make it easy to extend basic website functionality.

"We've encouraged an economy around being able to productize add-ons. A small business can install a Joomla site by following a five-step tutorial on the Web, download the add-ons in a single zip file and end up with a professional site," said Ozimek.

Ozimek said that small businesses typically use Joomla-based sites for standard brochure-like websites, to add functionality to communicate with customers using support ticketing or for ecommerce.

The SMB market is where Joomla earned its reputation, but now all eyes are on the enterprise and what Joomla can do there.

Visit link:
Joomla jumps to the enterprise

SUSS MicroTec launches RCD8: The new Resist Coat and Develop Platform

SSS MicroTec AG / Key word(s): Enterprise/ SUSS MicroTec launches RCD8: The new Resist Coat and Develop Platform DGAP-Media / 19.03.2012 / 18:21 =-------------------------------------------------------------------- PRESS RELEASE SUSS MicroTec launches RCD8: The new Resist Coat and Develop Platform Garching, GERMANY, March 19, 2012 - SUSS MicroTec, a leading supplier of equipment and process solutions for the semiconductor and related markets, launched the RCD8, a new manual Resist Coat and Develop Platform for substrates. The new platform offers a high application variety coupled with low investment costs as well as an easy transfer of processes from the RCD8 manual platform to a SUSS MicroTec production tool. The RCD8 is the only tool in the market that offers the option to convert from a spin coater with the patented GYRSET closed cover coating technology to a spray developer within a few minutes. This coat and develop platform can be custom tailored anywhere from e.g. a basic manual spin coater to a semi-automated GYRSET enhanced coater and puddle & spray developer tool, serving for daily R&D work up to small scale production. In the past multiple dedicated tools of our Delta Series were used for specific applications in MEMS, advanced packaging, LED or the R&D market. The different types of tools are now brought together in the RCD8 platform, which covers all necessary coating and developing processes for these applications. As an additional option the patented GYRSET rotating closed cover coating technology can be integrated into the RCD8 spin coating module. For various photoresists and applications, the GYRSET technology enables a wider process window and reduces material consumption significantly. Furthermore this technology allows even square substrates and pieces to be coated all the way to the corners with a homogenous resist thickness. 'Whenever process changes are required over time, this versatile tool can be field upgraded with various options to perfectly meet the actual needs of our customers', says Frank P. Averdung, President and CEO of SUSS MicroTec. 'With its large variety of available chucks and configurations, literally all kind of substrate materials and shapes can be coated and developed on the RCD8.' About SUSS MicroTec SUSS MicroTec, listed on TecDAX of Deutsche Boerse AG, is a leading supplier of equipment and process solutions for microstructuring in the semiconductor industry and related markets. In close cooperation with research institutes and industry partners SUSS MicroTec contributes to the advancement of next-generation technologies such as 3D Integration and Nano Imprint Lithography as well as key processes for MEMS and LED manufacturing. With a global infrastructure for applications and service SUSS MicroTec supports more than 8,000 installed systems worldwide. SUSS MicroTec is headquartered in Garching near Munich, Germany. For more information, please visit http://www.suss.com. Contact: SUSS MicroTec AG Franka Schielke Schleissheimer Strasse 90 85748 Garching, Deutschland Tel.: +49 (0)89 32007-161 Fax: +49 (0)89 32007-451 Email: franka.schielke@suss.com End of Media Release =-------------------------------------------------------------------- 19.03.2012 Dissemination of a Press Release, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at http://www.dgap-medientreff.de and http://www.dgap.de =-------------------------------------------------------------------- Language: English Company: SSS MicroTec AG Schleissheimer Strasse 90 85748 Garching Germany Phone: +49 (0)89 32007-161 Fax: +49 (0)89 32007-451 E-mail: ir@suss.com Internet: http://www.suss.com ISIN: DE000A1K0235 WKN: A1K023 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Dsseldorf, Hamburg, Mnchen, Stuttgart End of News DGAP-Media =-------------------------------------------------------------------- 161259 19.03.2012

(END) Dow Jones Newswires

March 19, 2012 13:21 ET (17:21 GMT)

Continue reading here:
SUSS MicroTec launches RCD8: The new Resist Coat and Develop Platform

Wanna Be Called IPPY Publishers?

Feature Self-Publishing Calls Itself Independent Publishing as Independent Publishers Search for a New Term

by Nina L. Diamond

We have a very big word problem.

The problem surrounding the words independent, indie, independent publisher, indie publisher, independent publishing, indie publishing, independent author, and indie author.

Small press used to be the term commonly used for an independent publishing house. Then, nearly 20 years ago, that term was replaced by the terms independent publisher and independent publishing house (often also called indies, indie publishers, and indie presses), because the word small was misleading and inaccurate. Many independent houses are quite large. Now, small press is a term only used to describe a press that's actually small: one that only publishes a few titles each year.

Independent publishers need a new term once again, not because that one isn't a good one, but because the stigma still attached to variations of the term self-publishing has led self-published authors to now call themselves independent (and indie) publishers and authors.

This has caused much confusion and frustration throughout the independent publishing wing of the book biz.

"Calling self-publishers... 'Independent' is a misnomer. It's like calling your pot dealer an independent pharmacist," wrote Jarek Steele, co-owner of Left Bank Books, a St. Louis independent bookstore, in a July 3, 2011 blog post about what self-publishers are really facing in the marketplace. "There are no quality controls, no support from professional publishers, no support from bookstores -- and that's just for the writer. The reader gets the short end, too."

Steele's post spoke for many in the publishing industry who share his views, and not just authors, editors, and publishers.

"I know I'll get a lot of flak for pointing out the uncomfortable truth, but it is the truth," he wrote. "Independent Publishers are businesses...those are true indies. Not the snakeoil salesman who promises riches beyond your wildest dreams -- for the right price. To call this Independent Publishing is insulting to the agents, publicists, sales reps, accountants, yes even credit reps in the publishing business, and truthfully it's insulting to independent bookstores. Just because you borrow a term and apply it to something else doesn't mean it's true. Words actually mean something."

Read the original here:
Wanna Be Called IPPY Publishers?

Add helpful information fields to a shared document

March 19, 2012, 7:53 AM PDT

Takeaway: To display specific information about a shared Word document including its author, you can use the fields feature.

When you share documents with others, its helpful to identify the document in various ways. You could display the documents file or author name, when the file was created or last revised, and by whom. Fortunately, using Word fields, displaying this type of information is easy.

First, decide where you want to display this type of information. Most likely, youll want to do so in the header or footer, but you can display it anywhere you like. Next, youll add the fields, as follows:

Its easy enough to include this type of information, but you might run into a problem. Fields dont update automatically. For instance, if you change the documents name, the FileName field will continue to display the documents previous file name until you update the FileName field. To update a field, simply select it and press [F9]. Theres your problem - you must remember to update the field to display the most up-to-date information!

You can add a macro that updates all of the documents field, but you must remember to execute it.If you forget, you end up distributing a document with the wrong information in the header.I dont have a solution that doesnt require a bit of user attention. Whether you create a macro button or attach the following macro to the files open or close process, the potential exists for an error of inattention:

This macro cycles through the StoryRanges collection, which references nearly everything in the document. Consequently, this macro updates every field in the document, so keep that in mind when applying itthat might not be what you want to do. Opening the file will execute it automatically.

Read the original post:
Add helpful information fields to a shared document